Current status of treatment in storage disorders.
D000818:Animals; D001234:Aspergillus niger; D002553:Cerebroside-Sulfatase / Q000627:therapeutic use; D002675:Child, Preschool; D003554:Cystinosis / Q000601:surgery; D004790:Enzyme Induction; D000795:Fabry Disease / Q000628:therapy; D005733:Gangliosidoses / Q000628:therapy; D005776:Gaucher Disease / Q000628:therapy; D005959:Glucosidases / Q000627:therapeutic use; D005966:Glucuronidase / Q000627:therapeutic use; D006008:Glycogen Storage Disease / Q000601:surgery / Q000628:therapy; D006527:Hepatolenticular Degeneration / Q000601:surgery; D006801:Humans; D016030:Kidney Transplantation; D007966:Leukodystrophy, Metachromatic / Q000628:therapy; D016031:Liver Transplantation; D008661:Metabolism, Inborn Errors / Q000628:therapy*; D009083:Mucopolysaccharidoses / Q000628:therapy; D009542:Niemann-Pick Diseases / Q000601:surgery; D011167:Portacaval Shunt, Surgical; D014184:Transplantation, Homologous
D002553:Cerebroside-Sulfatase; D005959:Glucosidases; D005966:Glucuronidase